Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexter Yan

Senior Reporter

Shanghai-based Dexter Yan is a senior writer covering Chinas surging pharma industry on the APAC Pharma news team. With a keen interest in commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest From Dexter Yan

China's CARsgen Raises $400m In Third-Largest Biotech IPO This Year

Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.

Financing China

'We Must Innovate': US Biotechs Chart New Growth Path In China

Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.

China Business Strategies

Two Years On, China’s STAR Attracts Star Players But With New Hurdles

Created to take on Nasdaq in the US, the Shanghai Stock Exchange’s STAR Market is celebrating its two-year anniversary with star performers such as CanSino. But its viability as an alternative will be tested by BeiGene, which is set to start trading in Shanghai following dual listings in New York and Hong Kong, with the latter continuing to attract other biopharma IPOs.

China Financing

China’s First ADC Secures Domestic Approval

RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.

China Approvals

China’s First ADC Secures Domestic Approval

RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.

China Approvals

ASCO: BeiGene, Novartis Herald Global PD-1 Contender In ESCC

The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.

ASCO Clinical Trials
See All
UsernamePublicRestriction

Register